Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Clio

Clio?uq=UG6efJS6
2009 FOUNDED
M&A STATUS
201-300 EMPLOYEES
M&A LATEST DEAL TYPE
$21M LATEST DEAL AMOUNT
Description

Provider of bio-medical services for regenerative medicine. The company is engaged in enhancing regenerative drug using Muse cells. It uses Multilineage-differentiating stress-enduring cells, which are safe, human-derived and pluripotent stem cells.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Parent Company
Life Science Institute
Primary Office
  • The Kaiteki Building
  • 1-13-4, Uchikanda, Chiyoda-ku
  • Tokyo, 102-0083
  • Japan

+81 00-0000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Clio’s full profile, request a free trial.

Clio Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 30-Jun-2015 $21M 0000 Completed Generating Revenue
1. Early Stage VC 15-Dec-2014 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Clio Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 04-Oct-2018 000000000000000000 Social/Platform Software
To view this company’s complete investment and acquisition history, request access »

Clio Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Venture Labo Investment Venture Capital Minority 000 0000 000000 0